Yang C Y, Gu Z W, Weng S A, Kim T W, Chen S H, Pownall H J, Sharp P M, Liu S W, Li W H, Gotto A M
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Arteriosclerosis. 1989 Jan-Feb;9(1):96-108. doi: 10.1161/01.atv.9.1.96.
We have analyzed low density lipoproteins (LDL) apolipoprotein (apop) B structure by direct sequence analysis of LDL apo B-100 tryptic peptides. Native LDL were digested with trypsin, and the products were fractionated on a Sephadex G-50 column. The partially digested apo B-100 still associated with lipids was recovered in the void volume (designated trypsin-nonreleasable, TN, peptides). The released peptides (designated trypsin-releasable, TR, peptides) in subsequent peaks were repurified on two successive high-performance liquid chromatography (HPLC) columns. The TN peak was delipidated and redigested with trypsin, and the resulting peptides were purified on two successive HPLC columns. Using this approach, we sequenced over 88% of LDL apo B-100, extending and refining our previous study (Nature 1986;323:738-742) which covered 52% of the protein. TN peptides made up 31%, and the TR peptides, 34% of the apo B-100 sequence; 23.7% were found under both TN and TR categories. Based on its differential trypsin releasability, apo B-100 can be divided into five domains: 1) residues 1----1000, largely TR; 2) residues 1001----1700, alternating TR and TN; 3) residues 1701----3070, largely TN; 4) residues 3071----4100, mainly TR and mixed; and 5) residues 4101----4536, almost exclusively TN. Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains. All 19 potential N-glycosylation sites were directly sequenced: 16 were found to be glycosylated and three were not. Three pairs of disulfide bridges were also mapped. Finally, a combination of cDNA sequencing, direct mRNA sequencing, and comparison of published apo B-100 sequences allowed us to identify specific amino acid residues within apo B-100 that seem to represent bona fide allelic variations. Our study provides information on LDL apo B-100 structure that will be important to our understanding of its conformation and metabolism.
我们通过对低密度脂蛋白(LDL)载脂蛋白(apop)B-100胰蛋白酶肽段进行直接序列分析,来研究LDL载脂蛋白B的结构。天然LDL用胰蛋白酶消化,产物在葡聚糖凝胶G-50柱上进行分级分离。与脂质仍结合的部分消化的载脂蛋白B-100在空体积部分回收(称为胰蛋白酶不可释放,TN,肽段)。后续峰中的释放肽段(称为胰蛋白酶可释放,TR,肽段)在两根连续的高效液相色谱(HPLC)柱上进行再纯化。TN峰进行脱脂处理后再用胰蛋白酶消化,所得肽段在两根连续的HPLC柱上进行纯化。采用这种方法,我们测定了LDL载脂蛋白B-100超过88%的序列,扩展并完善了我们之前的研究(《自然》1986年;323:738 - 742),之前的研究覆盖了该蛋白的52%。TN肽段占载脂蛋白B-100序列的31%,TR肽段占34%;23.7%同时存在于TN和TR类别中。基于其不同的胰蛋白酶可释放性,载脂蛋白B-100可分为五个结构域:1)第1至1000位残基,大部分为TR;2)第1001至1700位残基,TR和TN交替出现;3)第1701至3070位残基,大部分为TN;4)第3071至4100位残基,主要为TR且混合存在;5)第4101至4536位残基,几乎全为TN。结构域1包含载脂蛋白B中25个半胱氨酸残基中的14个。结构域4包含7个N-糖基化位点,并含有假定的受体结合结构域。对所有19个潜在的N-糖基化位点都进行了直接测序:发现16个被糖基化,3个未被糖基化。还确定了三对二硫键。最后,通过cDNA测序、直接mRNA测序以及与已发表的载脂蛋白B-100序列进行比较,我们能够鉴定出载脂蛋白B-100中似乎代表真正等位基因变异的特定氨基酸残基。我们的研究提供了关于LDL载脂蛋白B-100结构的信息,这对于我们理解其构象和代谢非常重要。